CITE-seq
CITE-seq combines single-cell RNA sequencing with protein detection to analyze cell populations in detail. Our platform facilitates comprehensive characterization of cell types, states, and interactions, enabling to profile immune cell responses,to identify rare cell populations, or to unravel disease mechanisms
ECCITE-seq
ECCITE-seq combines CRISPR perturbations, RNA sequencing, and protein detection at the single-cell level, enabling integrated analysis of transcriptome, genome, and proteome. This technique provides deep insights into cellular states and regulatory networks, serving as a powerful tool for CRISPR screens, functional genomics, and precision medicine research.
CRISPR Screening Platform
This academic platform proposes to perform CRISPR-based screens, enabling the comprehensive interrogation of the functional consequences of a genomic modification at the whole-genome scale, revealing how genomic alterations in coding or regulatory regions lead to phenotypic changes. The coordinator of the platform is Sandrine Roulland.
miRNA profiling
miRNA Profiling quantifies and characterizes microRNA expression to study their role in regulating gene expression. It helps identify biomarkers and potential therapeutic targets for cancer treatment.
3D bioprinting
3D Bioprinting allows the precise creation of complex tissue-like structures using cells and biomaterials. In oncology, it enables modeling of the tumor microenvironment to study cancer mechanisms and test new therapies.
Reverse Transcriptase Multiplex Ligation-dependant Probe Amplification (RT-MLPA)
RT-MLPA enables simultaneous detection and quantification of multiple RNA targets with high accuracy. In oncology, it is used to analyze gene expression signatures, identify biomarkers, and study disease mechanisms.
Proximity Ligation Assay (PLA)
Proximity Ligation Assay (PLA) enables precise detection and visualization of protein-protein interactions directly within cells. In oncology, it helps uncover signaling pathways, validate therapeutic targets, and reveal mechanisms driving cancer progression.
In vitro modelisation – Naïve B cells to plasma cell differentiation
We offer an in vitro model of B-cell terminal differentiation, based on the isolation and activation of donor-derived B-cells. This system allows functional studies of specific proteins through gene expression modulation with antisense technology and is fully characterized by immunoglobulin isoform analysis.
Long term in vitro culture of chronic lymphocytic leukemia primary cells
We provide a primary cell culture platform derived from patient samples, enabling precise gene expression modulation and comprehensive drug testing. This system supports target discovery and the evaluation of small molecules, antibodies, and CAR-T cell therapies.
Mouse Model for lymphoid neoplasms – DLBCL
Explore our mouse models designed respectively for the study of DLBCL, Burkitt Lymphoma, Amyloid light-chain amylosis, Multiple Myeloma, or Fanconi Syndrom, Light and heavy chain deposition disease. These models enable the identification of novel therapeutic targets as well as the evaluation of drug efficacy and toxicity.